New Rochelle, NY, December 15, 2014-Adiponectin, a collagen-like protein secreted by fat cells, derives from the ADIPOQ gene. Variations in this gene may increase risk for type 2 diabetes, cardiovascular disease, and various cancers. A new study that links specific variations in the ADIPOQ gene to either higher or lower colorectal cancer risk is published in Genetic Testing and Molecular Biomarkers, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the Genetic Testing and Molecular Biomarkers website until January 11, 2014.
Xin Guo, First Affiliated Hospital of Harbin Medical University, China, and Jiaqi Liu, Liuping You, Gang Li, Yuenan Huang, and Yunlong Li, Second Affiliated Hospital of Harbin Medical University, explored the relationship between two polymorphisms in the adiponectin gene and the risk of colorectal cancer in the article "Association Between Adiponectin Polymorphisms and the Risk of Colorectal Cancer." They also showed that these genetic variations may interact with environmental factors, such as red meat intake, to affect cancer risk.
"This paper suggests that adiponectin gene sequence may have significant prognostic value for colorectal cancer," says Kenneth I. Berns, MD, PhD, Editor-in-Chief of Genetic Testing and Molecular Biomarkers, and Director of the University of Florida's Genetics Institute, College of Medicine, Gainesville, FL.
About the Journal
Genetic Testing and Molecular Biomarkers is an authoritative peer-reviewed journal published monthly online with Open Access options and in print that reports on all aspects of genetic testing, including molecular and biochemical based tests and varied clinical situations; ethical, legal, social, and economic aspects of genetic testing; and issues concerning effective genetic counseling. Genetic Testing and Molecular Biomarkers is the official journal of Genetic Alliance. Complete tables of content and a free sample issue may be viewed on the Genetic Testing and Molecular Biomarkers website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy and OMICS: A Journal of Integrative Biology. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.